數年後，HPV 疫苗被證明對女孩非常有效

布列塔尼·巴爾加斯 / 2024 年 1 月 26 日 / Medscape 醫學新聞

要點：

根據《國家癌症研究所雜誌》發表的一項新研究，在 12 至 13 歲之間接種疫苗 Cervarix 可有效保護女性免受子宮頸癌的侵害。

方法：

•子宮頸癌是全球女性第四大常見癌症。

•提供二價疫苗 Cervarix 的計畫於 2007 年在英國啟動。

•計畫啟動後，從 12 歲開始，接種疫苗就成為女孩常規照護的一部分。

• 2020 年，研究人員透過蘇格蘭子宮頸癌篩檢系統收集了 447,845 名 1988 年至 1996 年間出生的女性的數據，以評估 Cervarix 在降低子宮頸癌發生率方面的功效。

•他們將每10萬人年的子宮頸癌發生率與女性的疫苗接種狀況、接種疫苗年齡以及收入、住房和健康等領域的貧窮數據相關聯。

後續：

•在 12 歲或 13 歲接受免疫的女性中，無論接種多少劑，均未發現子宮頸癌病例。

•無論貧窮狀況如何，在 14 至 18 歲之間接種疫苗並接受 3 劑疫苗的女性患子宮頸癌的機率低於未接種疫苗的女性（每 100,000 名女性 3.2 例，每 100,000 名女性 8.4 例）。

在實務中：

「然而，參與結果的篩檢和監測需要繼續，以評估自 2008 年蘇格蘭開始接種疫苗以來所使用的疫苗和劑量計畫變化的影響以及疫苗提供的保護的壽命。”

來源：

這項研究由蘇格蘭公共衛生局子宮頸篩檢臨床負責人 Timothy J. Palmer 博士領導。

限制：

只有 14,645 名女性只接受了一到兩劑疫苗，這可能影響了統計分析。

揭露：

這項研究由蘇格蘭公共衛生局資助。 Cuschieri 報告出席 HOLOGIC 和 Vaccitech 的顧問委員會會議。她的機構在過去3年中獲得了來自Cepheid、Euroimmun、GeneFirst、SelfScreen、Hiantis、Seegene、Roche、Hologic和Vaccitech的研究經費或免費支持經費。

引用此內容：幾年後，HPV 疫苗被證明對女孩非常有效 – Medscape – 2024 年 1 月 26 日。

HPV Vaccine Shown to Be Highly Effective in Girls Years Later

Brittany Vargas / January 26, 2024 / Medscape Medical News

TOPLINE:

The vaccine Cervarix was effective in protecting women from cervical cancer when administered between ages 12 and 13 years, according to a new study published in Journal of the National Cancer Institute.

METHODOLOGY:

• Cervical cancer is the fourth most common cancer among women worldwide.
• Programs to provide Cervarix, a bivalent vaccine, began in the United Kingdom in 2007.
• After the initiation of the programs, administering the vaccine became part of routine care for girls starting at age 12 years.
• Researchers collected data in 2020 from 447,845 women born between 1988 and 1996 from the Scottish cervical cancer screening system to assess the efficacy of Cervarix in lowering rates of cervical cancer.
• They correlated the rate of cervical cancer per 100,000 person-years with data on women regarding vaccination status, age when vaccinated, and deprivation in areas like income, housing, and health.

TAKEAWAY:

• No cases of cervical cancer were found among women who were immunized at ages 12 or 13 years, no matter how many doses they received. 
• Women who were immunized between ages 14 and 18 years and received three doses had fewer instances of cervical cancer compared with unvaccinated women regardless of deprivation status (3.2 cases per 100,00 women vs 8.4 cases per 100,000). 

IN PRACTICE:

“Continued participation in screening and monitoring of outcomes is required, however, to assess the effects of changes in vaccines used and dosage schedules since the start of vaccination in Scotland in 2008 and the longevity of protection the vaccines offer.”

SOURCE:

The study was led by Timothy J. Palmer, PhD, Scottish Clinical Lead for Cervical Screening at Public Health Scotland.

LIMITATIONS:

Only 14,645 women had received just one or two doses, which may have affected the statistical analysis. 

DISCLOSURES:

The study was funded by Public Health Scotland. Cuschieri reports attending an advisory board meeting for HOLOGIC and Vaccitech. Her institution received research funding or gratis support funding from Cepheid, Euroimmun, GeneFirst, SelfScreen, Hiantis, Seegene, Roche, Hologic, and Vaccitech in the past 3 years.

Send comments and news tips to news@medscape.net.

Cite this: HPV Vaccine Shown to Be Highly Effective in Girls Years Later – Medscape – January 26, 2024.